Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells.
## Primary Indications
* Short-term treatment (up to 8 weeks) of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* *Off-label:* Stress ulcer prophylaxis in critical care settings.
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or IV once daily. Duration: 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Hypersecretory Conditions:** Starting dose 40 mg twice daily. Doses up to 240 mg/day have been utilized; titration should be guided by clinical response and acid output measurements.
* **Stress Ulcer Prophylaxis (IV):** 40 mg daily (common institutional protocol; verify local guidelines).
## Pediatric Dosing
* **Erosive Esophagitis (Ages 5 years and older):**
* 15 kg to <40 kg: 20 mg once daily.
* 40 kg or greater: 40 mg once daily.
* *Note:* Safety and efficacy in children <5 years have not been established.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** Reduce frequency to every other day or limit to a maximum of 20 mg/day in severe impairment (Child-Pugh C).
## Contraindications
* Hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine-containing products (due to decreased absorption of the antiviral).
## Adverse Effects
* **Common:** Headache, diarrhea, abdominal pain, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (long-term use), interstitial nephritis, fracture risk (hip, wrist, spine), and cutaneous/systemic lupus erythematosus.
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of drugs like atazanavir, ketoconazole, and mycophenolate mofetil.
* **Methotrexate:** PPIs may increase methotrexate levels, particularly in high-dose therapy.
* **Clopidogrel:** Potential for decreased antiplatelet efficacy due to CYP2C19 inhibition (clinical significance remains debated; generally considered minor).
## Monitoring
* **Long-term:** Monitor magnesium levels, B12 status, and bone mineral density if risk factors are present.
* **Acute:** Monitor for signs of *C. difficile* (persistent watery stools, fever, abdominal cramping).
## Clinical Pearls
* **Administration:** Oral tablets may be taken with or without food. Do not split, crush, or chew enteric-coated tablets.
* **IV Administration:** Reconstituted IV pantoprazole should be administered as an infusion over 15 minutes.
* **Tapering:** Long-term users may experience rebound hypersecretion upon abrupt discontinuation; a gradual dose reduction is recommended.
* **Status:** Use the lowest effective dose for the shortest duration necessary to minimize risk of adverse events.
***
**Disclaimer:** This information is for educational purposes only. Always verify drug dosages, contraindications, and potential drug interactions with the latest prescribing information or institutional clinical guidelines before prescribing or administering medications.
